Product Images Clopidogrel

This text seems to be a table or graph without proper labels, making it impossible to generate a useful description.*

The text describes the results of a clinical trial that compares the effectiveness of two treatments (a placebo and clopidogrel) in reducing the combined risk of cardiovascular death, myocardial infarction, and stroke. The results are presented in a graph showing the cumulative event rate over the course of twelve months. The group receiving clopidogrel had a significantly lower event rate compared to the placebo group. Other standard therapies were also used during the trial.*

The text appears to be providing data on the cumulative event rates for death in the COMMIT study, comparing the placebo group (with 1845 deaths or 8.1% incidence) and the Clopidogrel group (with 1726 deaths or 1.5% incidence). It also suggests that there was a 5% reduction in the risk of death with Clopidogrel (p=0.03). However, the last line of the text is not readable and appears to be gibberish.*

This appears to be a statistical report showing the number and percentage of participants who experienced a certain event (possibly related to a clinical trial) for two groups labeled as "Phcebo" and "Ciopidogre." Additionally, there is mention of proportional risk and reduction. However, the context and meaning behind these numbers are not clear without further information.*

This appears to be a table showing various data points related to a medical study. There are columns for gender, age, time since onset, blood pressure, heart rate, and whether a fibrinolytic agent was given. There are also statistics comparing the effectiveness of the drug clopidogrel versus a placebo. However, there is not enough text to fully understand the table or what the study was investigating.*

This is a graph depicting the cumulative event rate in percentage for fatal or non-fatal vascular events in the CAPRIE study. The X-axis shows the months of follow-up, while the Y-axis shows the percentage of cumulative event rate. The graph appears to have three lines, possibly indicating different treatments or patient groups.*

This is a description of a medication with the NDC code 72578-012-06. Each tablet contains 97.830 mg of clopidogrel bisulfate USP equivalent to 75 mg of clopidogrel base. It is recommended to store the tablets at 20°C to 25°C and dispense them in a tight container. The medication is manufactured in India by Cadla Healthcare Ld. and distributed by Rx only Viona Pharmaceuticals. Additional information is available on the medication guide, and it is important to keep this and all drugs out of the reach of children.*